院内感染症治療の世界市場2021年ー2027年:感染症種類別(尿路感染症、人工呼吸器関連肺炎、手術部位感染症、血流感染症)、薬剤分類別、地域別

◆英語タイトル:Global Hospital acquired infections therapeutic Market Size study, by Infection Type (Urinary Tract Infections, Ventilator Associated Pneumonia, Surgical Site Infections, Bloodstream Infections), by Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs) and Regional Forecasts 2021-2027
◆商品コード:BZW21JU080
◆発行会社(リサーチ会社):Bizwit Research & Consulting
◆発行日:2021年6月18日
◆ページ数:約200
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:米国、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、中東
◆販売価格オプション(消費税別)
Single User(1名様閲覧用、印刷不可)USD4,950 ⇒換算¥544,500見積依頼/購入/質問フォーム
Enterprisewide(同一法人内共有可)USD6,250 ⇒換算¥687,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はBizwit Research & Consulting社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Bizwit Research & Consulting社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Bizwit Research社は、2020年におよそ105.4億ドルであった院内感染症治療の世界市場規模が、2021年から2027年の間に2.3%以上の健全な成長率で成長すると予測しています。本調査レポートでは、世界の院内感染症治療市場について調査・分析し、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、感染症種類別(尿路感染症、人工呼吸器関連肺炎、手術部位感染症、血流感染症、その他)分析、薬剤分類別(抗菌薬、抗ウイルス薬、抗真菌薬)分析、地域別分析、競争状況、調査プロセスなど、以下の項目でまとめております。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・院内感染症治療の世界市場規模:感染症種類別(尿路感染症、人工呼吸器関連肺炎、手術部位感染症、血流感染症、その他)
・院内感染症治療の世界市場規模:薬剤分類別(抗菌薬、抗ウイルス薬、抗真菌薬)
・院内感染症治療の世界市場規模:地域別
・競争状況
・調査プロセス
【レポートの概要】

Global Hospital acquired infections therapeutic Market is valued approximately USD 10.54 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 2.3 % over the forecast period 2021-2027. Hospital acquired infections is antifungal therapy which are added to empiric antibiotic coverage. Antiviral therapy can be used in the treatment of suspected disseminated viral infections. Rise in approval and launch of new drugs, increasing hospitalization due to rising burden of chronic diseases has led the adoption of Hospital acquired infections therapeutic across the forecast period. As rising population need large number of services which enforces rising in hospitalization due to chronic diseases. For Instance: As per the WHO in 2019, there were almost 17.9 million deaths from all types of cardiovascular diseases all over the world. This statistic describes the number of deaths caused by selected chronic diseases worldwide in 2019. However, declining demand for HAI drugs impedes the growth of the market over the forecast period of 2021-2027. Also, with the High prevalence of HAIs, is responsible to increase the market growth during the forecast period.

Global Hospital acquired infections therapeutic Market is segmented on the basis of geographical reason as Asia Pacific, North America, Europe, Latin America and Rest of the World. As far as the geographical region concerned, North America is deemed as leader of market and witnessed robust growth owing to growing non-invasive surgeries, adequate health infrastructure. Whereas, Asia-Pacific is coming up as one of the promising regions as huge market growth is observed due to factors such as rising population, growing health infrastructure would create profitable growth prospects for the Hospital acquired infections therapeutic Market across Asia-Pacific region

Major market player included in this report are:
Pfizer Inc.
MERCK & CO., Inc.
Bayer AG
GlaxoSmithKline
Daiichi Sankyo Company, Limited
AbbVie Inc.
Basilea Pharmaceutica AG
Abbott Inc.
F. Hoffmann-La Roche Ltd
Allergan Plc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Infection Type:
Urinary Tract Infections
Ventilator Associated Pneumonia
Surgical Site Infections
Bloodstream Infections
Others

By Drug Class:
Antibacterial Drugs
Antiviral Drugs
Antifungal Drugs

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:
Historical year – 2018, 2019
Base year – 2020
Forecast period – 2021 to 2027

Target Audience of the Global Hospital acquired infections therapeutic Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

【レポートの目次】

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)
1.2.1. Hospital acquired infections therapeutic Market, by region, 2019-2027 (USD Billion)
1.2.2. Hospital acquired infections therapeutic Market, by Infection Type, 2019-2027 (USD Billion)
1.2.3. Hospital acquired infections therapeutic Market, by Drug Class, 2019-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Hospital acquired infections therapeutic Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Hospital acquired infections therapeutic Market Dynamics
3.1. Hospital acquired infections therapeutic Market Impact Analysis (2019-2027)
3.1.1. Market Drivers
3.1.1.1. Rise in approval and launch of new drugs
3.1.1.2. Increasing hospitalization due to rising burden of chronic diseases
3.1.2. Market Challenges
3.1.2.1. Declining demand for HAI drugs
3.1.3. Market Opportunities
3.1.3.1. High prevalence of HAIs
Chapter 4. Global Hospital acquired infections therapeutic Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2018-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Hospital acquired infections therapeutic Market, by Infection Type
5.1. Market Snapshot
5.2. Global Hospital acquired infections therapeutic Market by Infection Type, Performance – Potential Analysis
5.3. Global Hospital acquired infections therapeutic Market Estimates & Forecasts by Infection Type 2018-2027 (USD Billion)
5.4. Hospital acquired infections therapeutic Market, Sub Segment Analysis
5.4.1. Urinary Tract Infections
5.4.2. Ventilator Associated Pneumonia
5.4.3. Surgical Site Infections
5.4.4. Bloodstream Infections
5.4.5. Others
Chapter 6. Global Hospital acquired infections therapeutic Market, by Drug Class
6.1. Market Snapshot
6.2. Global Hospital acquired infections therapeutic Market by Drug Class, Performance – Potential Analysis
6.3. Global Hospital acquired infections therapeutic Market Estimates & Forecasts by Drug Class 2018-2027 (USD Billion)
6.4. Hospital acquired infections therapeutic Market, Sub Segment Analysis
6.4.1. Antibacterial Drugs
6.4.2. Antiviral Drugs
6.4.3. Antifungal Drugs
Chapter 7. Global Hospital acquired infections therapeutic Market, Regional Analysis
7.1. Hospital acquired infections therapeutic Market, Regional Market Snapshot
7.2. North America Hospital acquired infections therapeutic Market
7.2.1. U.S. Hospital acquired infections therapeutic Market
7.2.1.1. Infection Type breakdown estimates & forecasts, 2018-2027
7.2.2. Canada Hospital acquired infections therapeutic Market
7.3. Europe Hospital acquired infections therapeutic Market Snapshot
7.3.1. U.K. Hospital acquired infections therapeutic Market
7.3.2. Germany Hospital acquired infections therapeutic Market
7.3.3. France Hospital acquired infections therapeutic Market
7.3.4. Spain Hospital acquired infections therapeutic Market
7.3.5. Italy Hospital acquired infections therapeutic Market
7.3.6. Rest of Europe Hospital acquired infections therapeutic Market
7.4. Asia-Pacific Hospital acquired infections therapeutic Market Snapshot
7.4.1. China Hospital acquired infections therapeutic Market
7.4.2. India Hospital acquired infections therapeutic Market
7.4.3. Japan Hospital acquired infections therapeutic Market
7.4.4. Australia Hospital acquired infections therapeutic Market
7.4.5. South Korea Hospital acquired infections therapeutic Market
7.4.6. Rest of Asia Pacific Hospital acquired infections therapeutic Market
7.5. Latin America Hospital acquired infections therapeutic Market Snapshot
7.5.1. Brazil Hospital acquired infections therapeutic Market
7.5.2. Mexico Hospital acquired infections therapeutic Market
7.6. Rest of The World Hospital acquired infections therapeutic Market

Chapter 8. Competitive Intelligence
8.1. Top Market Strategies
8.2. Company Profiles
8.2.1. Pfizer Inc.
8.2.1.1. Key Information
8.2.1.2. Overview
8.2.1.3. Financial (Subject to Data Availability)
8.2.1.4. Infection Summary
8.2.1.5. Recent Developments
8.2.2. MERCK & CO., Inc.
8.2.3. Bayer AG
8.2.4. GlaxoSmithKline
8.2.5. Daiichi Sankyo Company, Limited
8.2.6. AbbVie Inc.
8.2.7. Basilea Pharmaceutica AG
8.2.8. Abbott Inc.
8.2.9. F. Hoffmann-La Roche Ltd
8.2.10. Allergan Plc.
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption

List of Tables
TABLE 1. Global Hospital acquired infections therapeutic market, report scope
TABLE 2. Global Hospital acquired infections therapeutic market estimates & forecasts by Region 2018-2027 (USD Billion)
TABLE 3. Global Hospital acquired infections therapeutic market estimates & forecasts by Infection Type 2018-2027 (USD Billion)
TABLE 4. Global Hospital acquired infections therapeutic market by segment, estimates & forecasts, 2018-2027 (USD Billion)
TABLE 5. Global Hospital acquired infections therapeutic market by region, estimates & forecasts, 2018-2027 (USD Billion)
TABLE 6. Global Hospital acquired infections therapeutic market by segment, estimates & forecasts, 2018-2027 (USD Billion)
TABLE 7. Global Hospital acquired infections therapeutic market by region, estimates & forecasts, 2018-2027 (USD Billion)
TABLE 8. Global Hospital acquired infections therapeutic market by segment, estimates & forecasts, 2018-2027 (USD Billion)
TABLE 9. Global Hospital acquired infections therapeutic market by region, estimates & forecasts, 2018-2027 (USD Billion)
TABLE 10. Global Hospital acquired infections therapeutic market by segment, estimates & forecasts, 2018-2027 (USD Billion)
TABLE 11. Global Hospital acquired infections therapeutic market by region, estimates & forecasts, 2018-2027 (USD Billion)
TABLE 12. Global Hospital acquired infections therapeutic market by segment, estimates & forecasts, 2018-2027 (USD Billion)
TABLE 13. Global Hospital acquired infections therapeutic market by region, estimates & forecasts, 2018-2027 (USD Billion)
TABLE 14. U.S. Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 15. U.S. Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 16. U.S. Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 17. Canada Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 18. Canada Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 19. Canada Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 20. UK Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 21. UK Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 22. UK Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 23. Germany Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 24. Germany Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 25. Germany Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 26. RoE Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 27. RoE Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 28. RoE Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 29. China Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 30. China Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 31. China Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 32. India Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 33. India Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 34. India Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 35. Japan Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 36. Japan Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 37. Japan Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 38. RoAPAC Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 39. RoAPAC Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 40. RoAPAC Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 41. Brazil Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 42. Brazil Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 43. Brazil Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 44. Mexico Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 45. Mexico Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 46. Mexico Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 47. RoLA Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 48. RoLA Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 49. RoLA Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 50. Row Hospital acquired infections therapeutic market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 51. Row Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 52. Row Hospital acquired infections therapeutic market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 53. List of secondary sources, used in the study of global Hospital acquired infections therapeutic market
TABLE 54. List of primary sources, used in the study of global Hospital acquired infections therapeutic market
TABLE 55. Years considered for the study
TABLE 56. Exchange rates considered

List of figures
FIG 1. Global Hospital acquired infections therapeutic market, research methodology
FIG 2. Global Hospital acquired infections therapeutic market, market estimation techniques
FIG 3. Global market size estimates & forecast methods
FIG 4. Global Hospital acquired infections therapeutic market, key trends 2020
FIG 5. Global Hospital acquired infections therapeutic market, growth prospects 2021-2027
FIG 6. Global Hospital acquired infections therapeutic market, porters 5 force model
FIG 7. Global Hospital acquired infections therapeutic market, pest analysis
FIG 8. Global Hospital acquired infections therapeutic market, value chain analysis
FIG 9. Global Hospital acquired infections therapeutic market by segment, 2018 & 2027 (USD Billion)
FIG 10. Global Hospital acquired infections therapeutic market by segment, 2018 & 2027 (USD Billion)
FIG 11. Global Hospital acquired infections therapeutic market by segment, 2018 & 2027 (USD Billion)
FIG 12. Global Hospital acquired infections therapeutic market by segment, 2018 & 2027 (USD Billion)
FIG 13. Global Hospital acquired infections therapeutic market by segment, 2018 & 2027 (USD Billion)
FIG 14. Global Hospital acquired infections therapeutic market, regional snapshot 2018 & 2027
FIG 15. North America Hospital acquired infections therapeutic market 2018 & 2027 (USD Billion)
FIG 16. Europe Hospital acquired infections therapeutic market 2018 & 2027 (USD Billion)
FIG 17. Asia pacific Hospital acquired infections therapeutic market 2018 & 2027 (USD Billion)
FIG 18. Latin America Hospital acquired infections therapeutic market 2018 & 2027 (USD Billion)
FIG 19. Global Hospital acquired infections therapeutic market, company market share analysis (2020)


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[院内感染症治療の世界市場2021年ー2027年:感染症種類別(尿路感染症、人工呼吸器関連肺炎、手術部位感染症、血流感染症)、薬剤分類別、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆